NCT00034346View on ClinicalTrials.gov

ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)

PHASE2CompletedINTERVENTIONAL
Enrollment

194

Participants

Timeline

Start Date

January 31, 2002

Conditions
Non-Small Cell Lung CancerNeoplasm MetastasisLung Cancer
Interventions
DRUG

ABX-EGF

DRUG

paclitaxel

DRUG

carboplatin

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT00034346 - ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter